Theory Paper IIDrNB Cardiology – Theory Notes

ASSESSMENT OF REVERSIBILITY OF PAH

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ICLINICAL RATIONALE AND PATHOPHYSIOLOGICAL SPECTRUM

  • The Core Clinical Question: In patients with Congenital Heart Disease and systemic-to-pulmonary shunts (ASD, VSD, PDA, AVSD) complicated by Pulmonary Arterial Hypertension (PAH-CHD), assessment of reversibility determines whether elevated Pulmonary Vascular Resistance (PVR) is driven by reversible muscular vasoconstriction and medial hypertrophy (Heath-Edwards Grades I to III) or irreversible obliterative intimal fibrosis, plexiform lesions, and necrotizing arteritis (Heath-Edwards Grades IV to VI).
  • The Clinical Stakes: Closing a shunt when PVR is still reversible halts pulmonary vascular disease and normalizes life expectancy; conversely, closing a shunt (“eliminating the RV pop-off safety valve”) when PVR is irreversibly fixed precipitates post-operative right ventricular failure, low cardiac output, and worse long-term survival than leaving the patient in Eisenmenger syndrome.

IINON-INVASIVE CLUES OF REVERSIBILITY VS. IRREVERSIBILITY (CLINICAL, ECG, CXR, ECHO)

  • Bedside Clinical and Oximetry Clues:
    • Favors Reversibility (Left-to-Right Dominant Shunt): Hyperdynamic precordium, displaced LV apex, preserved loud holosystolic (VSD) or continuous (PDA) shunt murmur, apical diastolic flow rumble (indicating Qp:Qs >2:1 across the mitral valve), and resting and post-exercise (6MWT) SpO2 >= 95% (in both upper and lower limbs).
    • Favors Irreversibility (Bidirectional / Eisenmenger Shunt): Quiet precordium with parasternal RV heave, palpable P2, disappearance of the VSD/PDA shunt murmur, high-pitched Graham Steell PR murmur, and resting or exercise-induced arterial desaturation (SpO2 <90%) or differential toe cyanosis/clubbing.
    • 12-Lead ECG and Chest Radiograph (CXR):
    • Favors Reversibility: Biventricular hypertrophy (BVH) or isolated LV volume overload (tall R waves with deep narrow Q waves in V5–V6) on ECG; cardiomegaly with pulmonary plethora extending to the outer third of the lung fields on CXR.
    • Favors Irreversibility: Pure Right Ventricular Hypertrophy (RVH) with tall monophasic R in V1 and loss of lateral Q waves on ECG; normal heart size with massive central PA aneurysmal dilatation and peripheral vascular “pruning” (oligemic outer lung fields) on CXR.
    • Transthoracic Echocardiography:
    • Favors Reversibility: Left Atrial and Left Ventricular enlargement (confirming high pulmonary venous return), pure left-to-right color Doppler flow across the defect, and high-velocity shunt gradient.
    • Favors Irreversibility: Normal/small underfilled LA and LV with dilated hypertrophied RV, low-velocity bidirectional or right-to-left shunt flow across the defect, and interventricular septal flattening.

IIIINVASIVE HEMODYNAMIC CRITERIA ON RIGHT HEART CATHETERIZATION (ESC 2020 ACHD VS. PEDIATRIC INDEXED CRITERIA)

  • Adult Congenital Heart Disease (ESC 2020 ACHD Guidelines — Absolute PVR in Wood Units):
    • PVR less than 3 Wood Units (WU) with a Significant Shunt (Ventricular Volume Overload): Class I (Recommended) for standard percutaneous or surgical shunt closure.
    • PVR 3 to less than 5 WU with Qp:Qs > 1.5: Class IIa (Should Be Considered) for closure when significant left-to-right shunting persists without exercise desaturation.
    • PVR >= 5 WU: Immediate standard closure is contraindicated (see Treat-and-Repair below for ASD vs. careful expert evaluation in VSD/PDA if Qp:Qs >1.5).
    • Eisenmenger Physiology (PVR >= 5 WU with Qp:Qs < 1.5 or Right-to-Left Shunt): Class III (Harm — Strictly Contraindicated).
    • Pediatric / Indexed PVR Criteria (AHA / Pediatric PH Consensus — PVRi in Wood Units·m2 and Rp/Rs Ratio):
    • PVRi < 4 WU·m2 and Rp/Rs < 0.3: Safe for complete defect closure.
    • PVRi 4 to 8 WU·m2 or Rp/Rs 0.3 to 0.5 (“The Grey Zone”): Requires Acute Vasoreactivity Testing (AVT), trial balloon occlusion, or targeted medical pretreatment (often repaired with a fenestrated patch/device).
    • PVRi > 8 WU·m2 or Rp/Rs > 0.5 (Unresponsive to AVT): High risk of irreversible PVOD; defect closure is generally contraindicated.
Assessment Domain Favors Reversible PAH (Operable Shunt) Borderline / “Grey Zone” Favors Irreversible PVOD / Eisenmenger (Inoperable)
Resting & Exercise SpO2 >=95% at rest and on 6MWT (hands & feet) Mild drop on peak exercise <90% at rest or exercise; differential cyanosis/clubbing
CXR & ECG Cardiomegaly + plethora; BVH / LV volume overload (qR in V5–V6) Moderate cardiomegaly; BVH Normal CT ratio + peripheral pruning; pure RVH
Echocardiography Dilated LA & LV; pure L-to-R shunt Predominant L-to-R with brief R-to-L Small LA/LV; dilated RV; bidirectional / R-to-L shunt
ESC 2020 Adult PVR (WU) PVR < 3 WU (significant shunt) — Class I PVR 3 to <5 WU (Qp:Qs >1.5) — Class IIa PVR >= 5 WU with Qp:Qs <1.5 / R-to-L — Class III
Pediatric Indexed PVRi (WU·m2) PVRi < 4 WU·m2 and Rp/Rs < 0.3 PVRi 4–8 WU·m2 (Perform AVT) PVRi > 8 WU·m2 and Rp/Rs > 0.5 despite AVT

IVACUTE VASOREACTIVITY TESTING (AVT) AND TRIAL OCCLUSION IN THE CATH LAB

  • Important ESC 2020 Adult vs. Pediatric Nuance: While the 2020 ESC ACHD Guidelines note that acute vasodilator testing in adults has not been prospectively validated to predict late outcome and rely primarily on baseline PVR (<5 WU) and the Treat-and-Repair response, AVT remains widely used in pediatric and Indian tertiary centers for patients in the PVRi 4 to 8 WU·m2 grey zone:
  • Agents: Inhaled Nitric Oxide (10 to 40 ppm) + 100% Oxygen (or inhaled Iloprost / IV Epoprostenol). When calculating Fick Qp during 100% O2 inhalation, dissolved plasma O2 (0.003 x PO2) must be included in the Fick denominator.
  • Pediatric Operability Criteria on AVT (Barst / Lopes Criteria): A greater than 20 percent decrease in PVRi and Rp/Rs, achieving a final PVRi less than 6 WU·m2 and a final Rp/Rs ratio less than 0.3, accompanied by an increase in Qp:Qs. (Note: These shunt operability criteria are distinct from the Sitbon criteria [mPAP drop >=10 mmHg to <=40 mmHg], which are used only in Idiopathic PAH to select Calcium Channel Blocker therapy.)
  • Trial Balloon / Device Occlusion in Large PDA or ASD: Temporary 15-to-20-minute occlusion of a borderline PDA or ASD while recording simultaneous PA and systemic aortic pressures: a >20 to 25 percent drop in PA pressure (or PA/Ao systolic ratio falling <0.5) with preserved systemic aortic pressure and cardiac output supports closure (often using a fenestrated device).

VTHE “TREAT-AND-REPAIR” STRATEGY AND THE INDIAN CONTEXT

  • “Treat-and-Repair” Protocol: In patients presenting with baseline PVR >= 5 WU (or PVRi 6 to 8 WU·m2) who still exhibit a net left-to-right shunt, initiating 6 to 12 months of targeted PAH pharmacotherapy (Endothelin Receptor Antagonist [Bosentan/Macitentan] + PDE-5 Inhibitor [Sildenafil/Tadalafil]) followed by a repeat RHC allows fenestrated defect closure (creating a 4 to 6 mm unidirectional or calibrated pop-off) if PVR falls to less than 5 WU with Qp:Qs greater than 1.5, with lifelong continuation of PAH drugs post-closure.
  • Practical Considerations in the Indian Context:
    • Hydration and Altitude: Ensure patients are normovolemic and free of acute lower respiratory infection or severe anemia prior to RHC, as dehydration and hypoxia falsely elevate PVR.
    • Abandonment of Open Lung Biopsy: Open lung biopsy for Heath-Edwards histological grading is obsolete and not recommended due to high perioperative mortality in PAH and non-uniform patchy distribution of plexiform lesions.

Key references

  • Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
  • Humbert M, Kovacs G, Hoeper MM, et al.: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, European Heart Journal, 2022.
  • Lopes AA, O’Leary PW: Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease, Cardiology in the Young, 2009.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.